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Background: Vancomycin-resistant enterococci are a leading cause of hospital-acquired urinary tract infection and
a growing concern for the clinician. The aim of this study was to evaluate the effectiveness of daptomycin in the
treatment of patients with vancomycin-resistant enterococcal urinary tract infection treated in our 200-bed
community-based institution.
Methods: Patients with confirmed symptomatic vancomycin-resistant enterococcal urinary tract infection identified
by infectious disease consultation between January 1, 2007, and December 8, 2009, vancomycin-resistant
enterococci–positive urine culture, and urinary symptoms and/or pyuria on urinalysis, and treated with daptomycin,
were included in this case series. Daptomycin was generally administered at a planned dosage regimen of
≥5 mg/kg every 24 hours in patients with normal to moderately impaired kidney function or every 48 hours in
patients with severe kidney disease. Microbiologic cure was defined as eradication of vancomycin-resistant
enterococci in urine cultures taken after the completion of daptomycin treatment. Clinical cure was defined by
symptom resolution, as assessed by the infectious disease clinician caring for the patient.
Results: Included in this case series are 10 patients who received daptomycin for confirmed vancomycin-resistant
enterococcal urinary tract infection. Patients had a history of extensive hospital stays. Chart review revealed that all
levels of kidney function (3, 2, 3, and 2 patients with kidney disease classified as normal, mild, moderate, and
severe/kidney failure, respectively) were represented in the sample and that patients with (n = 5) or without (n = 5)
previous urinary tract infection and with (n = 3) or without (n = 7) Foley catheters were included. Treatment with
daptomycin achieved clinical cure and vancomycin-resistant enterococcal eradication in all cases in this series.
Conclusion: Treatment with daptomycin was well tolerated and effective in all patients in this series, regardless of
renal function, history of urinary tract infection, or Foley catheter use. This study adds to emerging clinical evidence
that daptomycin is a valuable treatment for vancomycin-resistant enterococcal urinary tract infection.
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In the United States, the Gram-positive bacterium
Enterococcus accounts for 12% of all cases of hospital-
acquired infection and is most often implicated in uri-
nary tract infections (UTIs) [1-3]. Recent data show that
approximately 33% of all clinical enterococcal isolates in* Correspondence: rabiesfreeworld@yahoo.com
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(VRE) [2]. In North America, VRE are mainly derived from
the species Enterococcus faecium (92.8%) and Enterococcus
faecalis (6.7%) [4]. In the past decade, VRE have become
increasingly involved in nosocomial infections in the
United States [5,6], which has resulted in excessive morbid-
ity, mortality, and health care costs [7]. Nearly 10% of all
urinary enterococcal isolates in the United States are VRE;
most of these are also E. faecium (88.4%) [3].
Because VRE, particularly E. faecium strains, exhibit re-
sistance to many antimicrobials traditionally used to targetntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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with VRE UTIs remains a challenge for the clinician [8]. In-
deed, no drugs are approved by the US Food and Drug Ad-
ministration (FDA) for the treatment of patients with VRE
UTIs, and reliable clinical data about the optimal manage-
ment of VRE UTIs are lacking in the scientific literature
[7]. Among the therapeutic options to be considered are
those that have demonstrated activity against VRE in vitro,
including older agents such as doxycycline, fosfomycin, and
nitrofurantoin and newer agents such as daptomycin,
linezolid, quinupristin–dalfopristin, and tigecycline [3,7,9].
Daptomycin is a bactericidal cyclic lipopeptide approved
by the FDA for the management of complicated skin and
skin structure infections caused by susceptible isolates of a
variety of Gram-positive bacteria, including methicillin-
resistant Staphylococcus aureus, and for the management
of bacteremia, including that associated with right-sided
infective endocarditis, caused by methicillin-susceptible
and methicillin-resistant isolates of S. aureus [10]. Al-
though the approved use of daptomycin in enterococcal
infections is limited to the treatment of patients with com-
plicated skin and skin structure infections caused by
vancomycin-susceptible isolates of E. faecalis [10], 100%
and 99.7% of vancomycin-resistant E. faecalis and E.
faecium, respectively, were susceptible to daptomycin in
more than 700 nonurinary VRE strains collected in the
United States between 2007 and 2008 [11]. The
daptomycin minimal inhibitory concentration required for
90% inhibition (MIC90) of vancomycin-resistant E. faecalis
was determined to be 1 μg/mL, whereas that for
vancomycin-resistant E. faecium was 2 μg/mL [11]. The
use of daptomycin is a particularly promising pharmaco-
therapeutic approach against VRE UTIs because 50% to
70% of the dose is excreted unchanged in the urine
24 hours after intravenous administration compared with
30% to 40% for linezolid, 15% to 19% for quinupristin–
dalfopristin, and 20% to 30% for tigecycline [7]. Moreover,
another case series has described the successful use of
daptomycin in patients with VRE UTIs [12].
In light of the scarcity of treatment options for VRE
UTI and clinical data related to daptomycin use in this
setting, the purpose of this report is to describe the clinical
experience with daptomycin as part of the management of
VRE UTIs in our acute care hospital. Our objective is to
offer further evidence supporting daptomycin as a viable
approach to managing a continuing therapeutic challenge.
Methods
This study was conducted at St. Mary’s Hospital, a small
community-based institution with approximately 200
beds, serving an urban population in Waterbury,
Connecticut. Our catchment area included a number of
nursing homes that contributed up to one-third of our in-
patients. On request, one of the authors (SJS) providedexpertise in the management of infectious diseases (ID).
The current retrospective case series includes patients for
whom ID consultation was requested over a 3-year period
(from January 1, 2007, to December 8, 2009) and who
ultimately received daptomycin for treatment of symp-
tomatic VRE UTI. In summarizing the cases we managed
for this report, we sought approval from the ethics com-
mittee of our institution (“the Saint Mary’s Hospital IRB”)
(protocol 12-18-09). After IRB permission was granted,
written informed consent was obtained from all patients
for inclusion in this study and for publication of their
medical information. A copy of the written consent is
available for review by the editor of this journal.
A large majority of VRE-infected patients in our hos-
pital are seen by an ID specialist because of intrinsic lim-
itations in the treatment options and the hospital
requirement of gown-and-glove contact isolation proce-
dures for these patients. For this retrospective case
series, patients were identified for consultation after a
telephone call about a VRE-positive urine culture. To be
treated with daptomycin and included in this analysis,
patients had to exhibit urinary symptoms, pyuria (>5
white blood cells per high-power field), or both on uri-
nalysis with a positive VRE culture.
VRE susceptibility was determined according to a
VITEK 2 (bioMérieux, Inc, Durham, NC) microbial iden-
tification system, with daptomycin susceptibility deter-
mined by Etest (bioMérieux, Inc) on request. Patients who
had positive VRE urinary cultures without significant py-
uria on urinalysis were considered colonized rather than
infected and, therefore, were not included in this analysis.
Once a patient was determined to have a VRE UTI,
screening creatinine values were measured in all cases,
and creatine phosphokinase (CPK) levels were deter-
mined in most cases. Daptomycin was generally admin-
istered at a planned dosage regimen of ≥5 mg/kg every
24 hours (if creatinine clearance [CrCl] ≥30 mL/min) or
every 48 hours (if CrCl <30 mL/min). Dosage was deter-
mined based on actual body weight for all patients in
this analysis. A dose of ≥5 mg/kg was chosen to provide
ample urinary concentrations of the drug.
Clinical cure was defined by the resolution of symp-
toms in the best judgment of the ID clinician involved in
the care of the patient (SJS). These included urinary
symptoms such as dysuria, urinary frequency, and
changes in urine character. Other symptoms such as ab-
dominal pain, fever, malaise, and anorexia were also
monitored for improvement. Follow-up urinalysis and
urine culture were typically performed at the end of the
daptomycin treatment course. The presence or absence
of pyuria in urinalysis at the end of treatment was not in
itself a strict criterion for clinical cure because it might
have resulted from bladder irritation, drugs, or other
causes. Regardless of whether pyuria was initially present
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course, microbiologic data were examined to help deter-
mine whether microbiologic cure was achieved. Microbi-
ologic cure was defined by the eradication of VRE in
urine cultures taken after completion of the daptomycin
treatment course.
Results
Between January 1, 2007, and December 8, 2009, we
identified 10 patients with VRE UTIs who were treated
by daptomycin-based regimens at our institution. Base-
line characteristics of these patients are shown in Table 1;
all patients had cystitis. As is apparent from the medical
histories, most of the VRE UTIs were acquired in the
hospital. In addition, the patients had a variety of risk
factors typical for VRE infections, such as prolonged
hospital stays, multiple previous UTIs, uropathy includ-
ing the requirement for a long-term Foley catheter, and
multiple past courses of antibiotics [7].
Table 2 presents the details of the daptomycin-based
regimens for the management of VRE UTIs in our se-
lected patient cases. Dosages used were based on our
empirical experience because there are no recommenda-
tions in the literature with regard to daptomycin use in
the treatment of patients with VRE UTIs. Because of the
high therapeutic index and the fixed vial size for
daptomycin (500 mg), some variability in actual per-
weight dosing occurred. The unusually high dose used
in patient 3 (13 mg/kg every 24 hours in a 30-year-old
man with quadriplegia) is explained by the concomitant
management of a Staphylococcus spp. bacteremia.
Daptomycin-based courses of antibiotic treatment
achieved clinical cure and successful eradication of VRE in
all patients in this representative sample of a diverse pa-
tient population in our medical facility (Table 2). Indwell-
ing catheters are common sites of infection, and similar
results of daptomycin treatment were observed in patients
with and without Foley catheters. Daptomycin was effec-
tive at eradicating VRE in patients regardless of whether
they had had previous UTIs. Additionally, daptomycin
eradicated VRE regardless of the level of renal function.
Overall, daptomycin was well tolerated, and no reports of
adverse events such as alteration of kidney function,
muscle weakness or pain, and elevated levels of CPK en-
zymes were included. For most patients, CPK levels were
measured at the time of daptomycin therapy initiation and
once or twice more in the next 7 to 10 days. Even for the
patient receiving the highest dose (13 mg/kg, patient 3),
no elevation was above the normal CPK range.
Discussion
The data in this case series show daptomycin to be a
safe and effective therapeutic option in the treatment of
patients with VRE UTIs. Limitations of the present studyinclude the fact that this is a retrospective case series
with a small number of patients and clinical records that
are often limited and variable. Furthermore, because of
the paucity of data in the literature, it is unclear what
the most appropriate daptomycin dose is for the treat-
ment of VRE UTIs. Nevertheless, it is clear that VRE are
increasingly involved in nosocomial infections. Of con-
cern, VRE may transfer vancomycin resistance to other
bacterial species, including S. aureus [13]. Uncontrolled
dissemination of VRE infections within health care insti-
tutions has been facilitated by incautious contact with
contaminated medical equipment and surfaces, colo-
nized health care personnel, and infected patients [14].
For example, the spread of a strain of linezolid-resistant
VRE has been reported in one zone of a transplantation
unit despite extensive precautions [15].
Another major factor that has led to the spread of
VRE infection is poor infection control techniques that
rely on cephalosporins and other antibacterials inactive
against enterococci [8]. A recent report [7] found that
more than 30% of all clinical isolates of Enterococcus
were resistant to vancomycin, including more than 90%
of E. faecium isolates. For these reasons, appropriate
antibiotic susceptibility testing is a mainstay of good
clinical practice to limit the spread of multidrug-
resistant strains, and agents that have specific activity
against these strains must be used to eradicate these
difficult-to-treat infections.
The urinary tract is one of the main portals for entry
of VRE, so it is hardly surprising that the urinary tract is
a major site of infection [13]. Management of VRE UTIs
usually requires correction of any factors contributing to
the infection. Catheter removal, obstruction relief, ab-
scess drainage, and initiation of antimicrobial therapy
are all initial steps taken in clinical practice [7].
In this case series, patients with VRE UTIs were
treated with daptomycin, a cyclic lipopeptide antibiotic
that has rapid bactericidal activity against a variety of
Gram-positive pathogens [16]. Daptomycin acts by bind-
ing to bacterial cell membranes and inducing rapid
depolarization, which inhibits DNA, RNA, and protein
synthesis and leads to cell death [10]. In the 10 cases de-
scribed here, daptomycin was chosen as the treatment
option because of its efficacy profile, sensitivity testing,
and low resistance rates for both major species of
Enterococcus.
Another important consideration when appropriate
treatment for VRE UTI is chosen is the presence of in-
tact drug at the site of infection [16]. Daptomycin is
eliminated primarily by the kidney; approximately 52% is
excreted unchanged into the urine after intravenous ad-
ministration [10]. Other agents active against VRE, such
as linezolid, quinupristin–dalfopristin, and tigecycline,
have a lower fraction of urinary excretion [7], which may

















1 72/F 67 Long hospital stay after surgery for large mucinous
adenocarcinoma of the ovary; ADM: lethargy
thought secondary to sedative overdose
No No 0.6/90 40-50 E. faecium 50,000 R: AMP, LNZ, TET, VAN;
S: GEN, QD, TIG
2 61/F 107 MS, neurogenic bladder; ADM: MS flare,
Pseudomonas spp. UTI treated with CIP
Yes Yes 0.8/100 60-65 E. faecium 30,000 R: PCN, TET, VAN; I: NFT; S: DAP
3 30/M 66 C5 quadriplegia, neurogenic bladder, recent UTIs
caused by Pseudomonas aeruginosa; ADM: abdominal
pain, cloudy urine, treated empirically with TOB
Yes No 0.2/>120 >100 E. faecalis 100,000 R: TET, VAN; S: DAP, PCN
Mild kidney disease (CKD 2)
4 70/F 66 Neurogenic bladder, nephrolithiasis; ADM: lethargy,
hypotension
Yes Yes 0.6/83 25-30 E. faecium >100,000 R: AMP, PCN, VAN
5 67/F 109 ADM: acute on chronic respiratory failure due to CHF,
hypoventilation secondary to obesity; initially required
intubation and ventilation in the ICU, developed fever
(101°F); initially unspecified Enterococcus infection
treated with VAN and CEF
No No 1.4/63 NP E. faecium 5000 R: AMP, NFT, VAN
Moderate kidney disease (CKD 3)
6 83/F 55 Acute exacerbation of COPD No No 1.1/34 TNTC E. faecium >100,000 R: PCN, TET, VAN; I: NFT
7 83/F 77 Stays at a nursing home; recently hospitalized for
stenting of right femoral artery for vascular disease
No No 1.2/46 25-50 E. faecium 40,000 R: NFT, PCN, TET, VAN; S: DAP
8 86/M 70 CKD stage 3, nephrolithiasis, obstructive uropathy with
benign prostatic hypertrophy, recent UTI caused by
E. coli and P. aeruginosa; ADM: bloody urine, initial
evaluation revealed infection with E. coli and P. aeruginosa,
treated with CEF
Yes Yes 1.1/43 10-15 E. faecium 80,000 R: PCN, TET, VAN
Severe kidney disease/kidney failure (CKD 4–5)
9 90/F 60 Severe dementia, stays at extended-care facility; ADM:
decreased oral intake, abdominal pain, fever (100.9°F)
Yes No 1.1/26 TNTC E. faecium >100,000 R: AMP, CIP, NFT, TET, VAN
10 60/M 81 Liver transplant for hepatitis C cirrhosis; ADM: chest pain,
E. coli empyema complicating previous CABG surgery
No No 4.1/19 NP E. faecium 100,000 R: DOX, PCN, VAN
ADM admission, AMP ampicillin, CABG coronary artery bypass graft, CEF ceftazidime, CFU colony-forming units, CHF congestive heart failure, CIP ciprofloxacin, CKD chronic kidney disease, COPD chronic obstructive
pulmonary disease, Cr creatinine, CrCl creatinine clearance, DAP daptomycin, DOX doxycycline, GEN gentamicin, I intermediate, ICU intensive care unit, LNZ linezolid, MS multiple sclerosis, NFT nitrofurantoin, NP not
performed, PCN penicillin, QD quinupristin–dalfopristin, R resistant, S susceptible, TET tetracycline, TIG tigecycline, TNTC too numerous to count, TOB tobramycin, UTI urinary tract infection, VAN vancomycin, WBC/hpf





















Table 2 Details of management of VRE UTIs and outcome of daptomycin course
Patient Daptomycin dosing Daptomycin treatment duration Concomitant antibiotics Posttreatment urine culture
Normal kidney function
1 7.5 mg/kg q24h 7 days None VRE eradicated
2 8 mg/kg q24h 3 days None VRE eradicated
3 13 mg/kg q24h* 10 days None VRE eradicated
Mild kidney disease (CKD 2)
4 5 mg/kg q24h 3 days Fluconazole VRE eradicated
5 5 mg/kg q24h 3 days None VRE eradicated
Moderate kidney disease (CKD 3)
6 5 mg/kg q24h 3 days None VRE eradicated
7 5 mg/kg q24h 3 days Gentamicin 120 mg once a day 5 days after initiation of daptomycin;
VRE eradicated
8 5 mg/kg q24h 3 days None VRE eradicated
Severe kidney disease/kidney failure (CKD 4–5)
9 5 mg/kg q24h† 3 days None VRE eradicated
10 5 mg/kg q48h 3 days None VRE eradicated; patient died 2 days
later (not related to infection)
CKD chronic kidney disease, q24h once every 24 hours, q48h once every 48 hours, VRE vancomycin-resistant enterococci.
As determined using the Cockcroft-Gault equation, CKD 2 = glomerular filtration rate (GFR) of 60–89 mL/min/1.73 m2, CKD 3 = GFR of 30–59 mL/min/1.73 m2, and
CKD 4–5 = GFR of <30 mL/min/1.73 m2.
Follow-up durations: microbiologic assessment (urine culture) ~3 days, clinical assessments up to ~7 days posttreatment.
*Use of unusually high per-weight dose was recommended by the ID specialist for the concomitant management of Staphylococcus spp. bacteremia.
†ID consult resulted in clinical decision to treat q24h rather than q48h for more rapid results in this patient.
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of VRE UTIs.
Most strains of VRE are resistant to penicillin and ampi-
cillin, although higher-dose ampicillin, doxycycline, and
nitrofurantoin remain viable treatment options. More
often, drug choices used to treat VRE include daptomycin,
linezolid, quinupristin–dalfopristin, and tigecycline. These
compounds have similarly low MIC values against VRE
species [7]. All these antibiotics except daptomycin exhibit
bacteriostatic properties; daptomycin is bactericidal [7].
Daptomycin has similar MIC values for E. faecium and E.
faecalis [7] and is effective in treating either pathogen.
Daptomycin resistance among VRE strains remains rare
[11]; numerous global surveillance studies have demon-
strated higher susceptibility levels in VRE strains using
daptomycin than in strains using linezolid or quinupristin–
dalfopristin [16]. Resistance to linezolid among VRE iso-
lates has been well described and is of increasing clinical
concern [16-19]. Quinupristin–dalfopristin has limited
activity against E. faecalis [7]. In addition, vancomycin-
resistant E. faecium strains have shown emerging resis-
tance to quinupristin–dalfopristin; 3.4% of urinary tract iso-
lates were resistant in a study at 28 medical centers in the
United States [3]. Use of quinupristin–dalfopristin is also
limited by its potential systemic and infusion site–related
adverse effects, including myalgia and arthralgia [7,13].
Our experience confirms and extends the findings of a
previous case series on the use of daptomycin for thetreatment of VRE UTIs. The previous study [12] of 5 hos-
pitalized patients with indwelling catheters and VRE UTIs
who received 5-day courses of daptomycin showed that all
patients achieved complete eradication of infection at
daptomycin doses of 1.4 to 3.7 mg/kg daily. Taken to-
gether, these case studies emphasize the importance of
further analyses to delineate the appropriate doses of
daptomycin for the treatment of patients with VRE UTIs.
Conclusions
In the current case series, daptomycin was shown to be
a safe and effective therapeutic option in the manage-
ment of VRE UTIs. Because of the increasing prevalence
of VRE infection and the limited treatment options avail-
able, we anticipate that management of VRE UTIs will
continue to be challenging for the clinician. Based on
our experience, we believe that daptomycin is a valuable
treatment option for problematic UTIs. These findings
must be confirmed in larger randomized clinical trials.
However, despite the lack of data about therapeutic op-
tions for VRE UTIs and the intrinsic limitations of de-
scriptive case reports, our positive experience with
daptomycin may be of value to the clinical community.
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